Friday, April 30, 2021

QualityStocksNewsBreaks – Healthtech Solutions Inc. (HLTT) Enters Precision Oncology Market Through Strategic Acquisition

 Healthtech Solutions (OTC: HLTT), focused on acquiring and investing in strategic cutting-edge health care technological opportunities, recently expanded its portfolio in a move that facilitated entry into the precision cancer care market. Varian Bio was added to the Healthtech Solutions’ umbrella via the parent company acquiring a wholly owned subsidiary, Healthtech Oncology Inc., which will own a 100% interest in Varian Bio. This move adds Varian Bio to HLTT’s growing portfolio to join MediScan Inc., a developer of technology that converts 2D images from portable ultrasound machines into digital 3D images, and RevHeart, a company advancing critical research into the treatment of COVID-related heart muscle injury. “Varian is in the pre-clinical stages of developing two aPKC iota inhibitors in user-preferred delivery methods to treat cancer. VAR-101 is being designed as a topical formulation for the treatment of basal cell carcinoma, the most common type of skin cancer, with about 3.6 million diagnoses each year in the U.S.,” reads a recent article. “VAR-102 is an oral formulation being developed for treating an array of solid tumors where there is existing evidence aPKCi inhibition would be beneficial, such as pancreatic, colorectal and non-small cell lung cancers (“NSCLC”). These indications represent areas of unmet need, as the fourth, third and second leading cause of cancer deaths, respectively, in the U.S. annually.”

To view the full article, visit https://ibn.fm/osNAV

About Healthtech Solutions Inc.

Healthtech Solutions is a reporting public company. The board of directors is focusing the company’s resources into creating a platform to acquire and/or invest in cutting-edge health care technology in the medical device biopharma and pharmaceutical fields. The goal is to bring these solutions to market.

To date, Healthtech Solutions has invested in three areas of medical technology breakthrough:

  • MediScan Inc., which is developing a technology that converts 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can provide the data equivalent to an X-ray, MRI or CT scan, without radiation and at a lower cost.
  • RevHeart Inc., which is advancing critical research into the treatment of COVID-related heart muscle injury.
  • Varian Biopharmaceutical Inc., a precision oncology company, is the first acquisition of Healthtech Oncology Inc.

Healthtech Solutions has a pipeline of additional acquisitions currently under due diligence.

NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Eyes Massive Potential Consumer Base

 HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leader in the health and wellness cannabidiol (“CBD”) industry, recently received conditional approval to launch its CBD products on the world’s largest cross-border online marketplace, Tmall Global. The approval effectively gives HempFusion the potential to reach more than 750 million new consumers and follows a similar move by its subsidiary, Probulin Probiotics LLC. Notably, the announcement is just one in a series of positive news about the company. “CBD.U became the first U.S.-based CBD and wellness products company to list directly on the Toronto Stock Exchange (‘TSX’) following the completion of a US$17 million initial public offering (‘IPO’) in January 2021,” reports a recent article. “Additionally, the company has witnessed an increase in online sales from 6% to 24% in the few months preceding the April 2021 update.”

To view the full article, visit https://ibn.fm/E13r3

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 U.S. states and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs, including tinctures, proprietary FDA Drug-listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on R&D, HempFusion has an additional 30 products under development. HempFusion is a board member of the U.S. Hemp Roundtable and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in-store or by visiting HempFusion online at www.Hempfusion.com or www.Probulin.com.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion  

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Is ‘One to Watch’

 

  • Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways
  • The company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas)
  • Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that offer increased efficacy and reduced risk of abuse or addiction
  • The company’s management team has decades of experience in the life sciences industry, including the pharmaceutical and biotechnology markets
  • Oncology therapeutics are expected to account for roughly 30% of all drug sales by 2024, representing a total market valued at approximately $200 billion

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

  • Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
  • Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
  • Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN(TM) Program

Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction

Tryp’s PFN(TM) program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica(R)), Duloxetine (Cymbalta(R)) and Milnacipran (Savella(R)), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (“YPO”) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

United Medical Equipment Business Solutions Network Inc. Provides Solutions for Safer Workplaces

 

  • Routine virus testing is effective overall employer strategy for providing employee safety and business continuity
  • More research needs to be done on how long vaccines are effective, if booster shots will be needed
  • Only 26% of the U.S. is fully vaccinated; vaccinated individuals can still spread the virus

United Medical Equipment Business Solutions Network provides solutions that fit the ever-changing needs of the nation’s workforce during the COVID-19 pandemic through the distribution of rapid antigen tests and COVID-19 rapid kit testing. As employers begin to reopen worksites, routine virus testing is an effective overall strategy for providing employee safety and business continuity.

Chief medical advisor to the president Anthony Fauci, MD, has stated that booster shots for COVID-19 may be needed (https://ibn.fm/NWcBr). The vaccines currently being offered are said to provide protection for at least six months, but more research needs to be done on how long they are effective. The appearance of COVID mutations may also lead to the need for boosters. Right now vaccination efficacy is simply a moving target because the vaccines have not been around long enough to know how long they will be effective fully.

To achieve herd immunity, Fauci has said that the country needs to have 70% to 85% of the country immune either through vaccinations or previous infection. As of April 21, 2020, around 26% of the population was fully vaccinated (https://ibn.fm/w57PZ).

The experts agree that it will take time to suppress the spread entirely. The fact that those who are vaccinated are still capable of spreading the virus to others makes the process even slower; the task becomes even more daunting as fewer Americans practice public health safety measures.

COVID-19 rapid kit testing is needed now more than ever. The pandemic isn’t over, despite the urgency to go back to life as usual. United Medical is making it possible for businesses and health-care facilities to maintain safety and health among workers and clients.

United Medical is a trusted supplier of personal protective equipment (“PPE”) as well as FDA-approved COVID-19 rapid antibody test kits and FDA – EUA authorized rapid antigen tests. The company works with its customers’ specific testing needs and goals to build a customized and flexible employee testing solution that works for the employer, the employees and the customer’s budget.

United Medical is committed to addressing the needs of America’s aging population throughout the global pandemic and far into the future. By offering COVID-19 rapid kit testing, the company is doing its part and continually evolving its efforts to protect the community from COVID-19.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) President Gives Positive Outlook for AR Industry in Recent Podcast Interview

 

  • Speaking in an interview with Oren Klaff, Nextech President Paul Duffy noted that AR technology, as a concept, was growing as more people understand its use
  • He foresees significant milestones and breakthroughs, as well as an extensive global adoption of AR technology
  • His prediction is in line with a recent industry report that shows that the AR market will grow at a CAGR of 43.8% from 2021 to 2028

According to a report by Grand View Research, the global augmented reality (“AR”) market is estimated to grow at a 43.8% CAGR from 2021 to 2028, reaching $340.2 billion up from a market size value of $26.75 billion. The report attributes this growth to new innovations in the AR space that have led to the adoption of this technology in multiple industries. Presently, more people are using AR-based tools and platforms to shop, interact with their peers on social media and learn, in turn, fueling growth (https://ibn.fm/u7wMy).

The report tells of a world that a 2017 Harvard Business Review (“HBR”) article predicted (https://ibn.fm/24iNX). The authors forecasted that AR, which was in its infancy at that time, would enter the mainstream and transform different industries and organizations, including learning institutions and social enterprises.

In an interview with bestselling author Oren Klaff on his “The Dealmaker Show” podcast (https://ibn.fm/OzLs9), Paul Duffy, President of Toronto-based Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), gave a positive outlook for the AR market and industry, indirectly seconding the predictions.

“The whole concept of augmented reality is just galloping in growth right now, not just in financial terms, but in mindshare, in people understanding its use. I personally believe that, over the next decade, augmented reality itself will become a new form of mass medium that we will all use to communicate at one level,” Duffy stated.

Duffy predicts that the next decade will witness significant AR technology milestones and breakthroughs that will lower the cost and size/weight of eyewear but still offer expanded functions and features, including support for multiple ways of controlling the devices. Moreover, he noted that breakthroughs leading to revolutionary experiences would hit the market in three to five years, effectively playing a role in making AR technology bigger and “omnipresent.”

“I’m seeing, at a global level, a large adoption of the technology. What I mean by this is there are more and more folks who are seeing its as a technology that they can apply, and they can use to gain value intrinsically in what they’re already doing,” Duffy continued.

Asked about businesses that should adopt AR, Duffy highlighted three key areas: e-commerce companies, hybrid and virtual events, and brands whose operations encompass advertising. He credited Nextech’s growth to its strong leadership team and the fact that it offers AR solutions for each of these three areas.

In April 2021, Nextech launched the LiveX Digital Experience Platform (“DXP”), its hybrid and virtual events platform, which it will use to stream an upcoming two-day event, leveraging its AR technological solutions to provide an engaging experience for attendees (https://ibn.fm/o75Ag). Similarly, the company launched an AR-capable Ad Network early this year. Nextech also offers AR-based e-commerce solutions, effectively taking part in the online commerce megatrend.

Thanks to its broad approach to offering innovative AR solutions, the company has witnessed tremendous growth year over year. In its recently released full-year report, for example, Nextech reported a 342% increase in revenue and a 320% growth in gross profits. Based on Paul Duffy’s positive outlook for the AR industry, Nextech looks poised to continue this growth through the coming years.

For more information, visit the company’s website at www.NextechAR.com.

NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF .

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – BAND Royalty Announces OpenSea NFT Music Collection

 BAND Royalty, an entertainment and technology-driven firm and a leading innovator of music-focused NFTs, has announced that it will be launching a unique collection of blockchain-secured BAND NFTs. Next month, the company anticipates releasing an exclusive collection of NFTs that connect fans with a catalog of music featuring musical artists Beyoncé, Jay-Z, Rihanna, Justin Timberlake and more. By obtaining a BAND NFT,  fans receive a stake in 50% of the royalties earned from the BAND Royalty offerings every time someone listens to a track. The company announced that it is releasing the collection of NFTs on OpenSea.io, the largest NFT marketplace in the world. With sales reaching more than $86 million in February alone, OpenSea provides a wide array of digital goods including collectibles, gaming items, domain names, digital art and, now music. The inaugural issuance of BAND NFTs will be available on May 5 and will be limited to only 3,000 NFTs initially, with a cap of 12,000 in subsequent offerings. Once buyers become holders of BAND NFTs, they will have the option to stake their BAND NFT tokens for a period of up to five years; the longer the stake, the more proportionally increased share of the royalties will be received. With this launch, BAND Royalty opens up music royalties to music lovers everywhere, providing an opportunity to earn royalties on top songs and blockbuster artists.

To view the full press release, visit https://ibn.fm/ZoHJe

About BAND Royalty

BAND Royalty is a platform founded by Barnaby Andersun and Noble Drakoln and operated by LIBERTY IS PTE LTD. The platform offers music fans the opportunity to earn a share of music streaming royalty by top artists worldwide in the BAND Royalty pool. BAND Royalty is revolutionizing the music world by using technology to help music fans connect in a brand-new way with musicians, allowing music lovers to earn revenue from their passion. To learn more about the company, visit www.BANDRoyalty.com.

NOTE TO INVESTORS: The latest news and updates relating to BAND are available in the company’s newsroom at https://ibn.fm/BAND

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php